Female Pattern Hair Loss
Conditions
Brief summary
This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Interventions
DRUGSpironolactone
This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
DRUGMinoxidil
This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
Sponsors
University of British Columbia
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must be premenopausal women older than 18 with female pattern hair loss.
Exclusion criteria
* Androgen excess * Other scalp or hair disorders * Contraindications to spironolactone treatment, especially pregnancy, electrolyte imbalances, history of breast cancer, or intake of interfering drugs * Contraindications to minoxidil treatment, especially patients who are allergic to this treatment or have a history of low blood pressure or irregular heart beats
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hair density | after 3, 6 and 9 months |
Secondary
| Measure | Time frame |
|---|---|
| percentage of subjects who experience side effects | — |
| subject assessment of treatment effect | — |
Countries
Canada
Outcome results
None listed